Comparison of respiratory therapy methods in patients with lung infection.

Comparative study of the effectiveness of calcitonin nebulizer in treatment of patients with ventilator-associated pneumonia in patients hospitalized in the ICU of Golestan Hospital, Ahvaz: A randomized clinical trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20251208068246N2

Enrollment

130

Registered

2026-05-12

Start date

2026-05-26

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pneumonia.

Interventions

Intervention 1: Intervention group: The treatment group is IV colistin (2.5–5 mg/kg/day) plus nebulized colistin (2 million IU q12h). IV colistin is infused at 2.5–5 mg/kg, 3 times a day every 8 hours

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Patients older than 18 years Patients with moderate (GCS 9-11) and severe (GCS <9) traumatic brain injury Clinical diagnosis of ventilator-associated pneumonia (VAP) caused by multidrug-resistant gram-negative bacilli according to CDC criteria Patient consent to participate in the study

Exclusion criteria

Exclusion criteria: Sensitivity to colistin Acute renal failure (CrCl <30 mL/min)

Design outcomes

Primary

Measure	Time frame
Clinical Pulmonary Infection Score (CPIS)Score. Timepoint: In time of treatment initiation up to discharge time. Method of measurement: Using CPIS score system including, respiratory symptoms, clinical findings, microbiology tests, sign of respiratory tract, risk factors, and inflammation symptoms.;Liver Function. Timepoint: Every day following treatment initiation. Method of measurement: Blood and urine tests.	—

Measure

Time frame

Clinical Pulmonary Infection Score (CPIS)Score. Timepoint: In time of treatment initiation up to discharge time. Method of measurement: Using CPIS score system including, respiratory symptoms, clinical findings, microbiology tests, sign of respiratory tract, risk factors, and inflammation symptoms.;Liver Function. Timepoint: Every day following treatment initiation. Method of measurement: Blood and urine tests.

—

Secondary

Measure	Time frame
Acute renal failure. Timepoint: Every day following treatment initiation. Method of measurement: Blood and urine tests.;Duration of mechanical intubation. Timepoint: Every day following treatment initiation. Method of measurement: Number of days of ventilator usage.;Duration of admission in ICU. Timepoint: The day of discharge from ICU. Method of measurement: Day count.;Mortality. Timepoint: 28 days following treatment initiation. Method of measurement: Alive or expired.	—

Measure

Time frame

Acute renal failure. Timepoint: Every day following treatment initiation. Method of measurement: Blood and urine tests.;Duration of mechanical intubation. Timepoint: Every day following treatment initiation. Method of measurement: Number of days of ventilator usage.;Duration of admission in ICU. Timepoint: The day of discharge from ICU. Method of measurement: Day count.;Mortality. Timepoint: 28 days following treatment initiation. Method of measurement: Alive or expired.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFereshte Amiri

Ahvaz University of Medical Sciences

amiri-f@ajums.ac.ir+98 61 3320 4536

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Jun 11, 2026